PT  - JOURNAL ARTICLE
AU  - Boddington, Nicola L
AU  - Charlett, Andre
AU  - Elgohari, Suzanne
AU  - Walker, Jemma L
AU  - McDonald, Helen I
AU  - Byers, Chloe
AU  - Coughlan, Laura
AU  - Vilaplana, Tatiana Garcia
AU  - Whillock, Rosie
AU  - Sinnathamby, Mary
AU  - Panagiotopoulos, Nikolaos
AU  - Letley, Louise
AU  - MacDonald, Pauline
AU  - Vivancos, Roberto
AU  - Edeghere, Obaghe
AU  - Shingleton, Joseph
AU  - Bennett, Emma
AU  - Grint, Daniel J
AU  - Strongman, Helen
AU  - Mansfield, Kathryn E
AU  - Rentsch, Christopher
AU  - Minassian, Caroline
AU  - Douglas, Ian J
AU  - Mathur, Rohini
AU  - Peppa, Maria
AU  - Cottrell, Simon
AU  - McMenamin, Jim
AU  - Zambon, Maria
AU  - Ramsay, Mary
AU  - Dabrera, Gavin
AU  - Saliba, Vanessa
AU  - Bernal, Jamie Lopez
TI  - COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis
AID  - 10.1101/2020.05.18.20086157
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.18.20086157
4099  - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20086157.short
4100  - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20086157.full
AB  - Objectives Following detection of the first virologically-confirmed cases of COVID-19 in Great Britain, an enhanced surveillance study was initiated by Public Health England to describe the clinical presentation, course of disease and underlying health conditions associated with infection of the first few hundred cases.Methods Information was collected on the first COVID-19 cases according to the First Few X WHO protocol. Case-control analyses of the sensitivity, specificity and predictive value of symptoms and underlying health conditions associated with infection were conducted. Point prevalences of underlying health conditions among the UK general population were presented.Findings The majority of FF100 cases were imported (51.4%), of which the majority had recent travel to Italy (71.4%). 24.7% were secondary cases acquired mainly through household contact (40.4%). Children had lower odds of COVID-19 infection compared with the general population.The clinical presentation of cases was dominated by cough, fever and fatigue. Non-linear relationships with age were observed for fever, and sensitivity and specificity of symptoms varied by age.Conditions associated with higher odds of COVID-19 infection (after adjusting for age and sex) were chronic heart disease, immunosuppression and multimorbidity.Conclusion This study presents the first epidemiological and clinical summary of COVID-19 cases in Great Britain. The FFX study design enabled systematic data collection. The study characterized underlying health conditions associated with infection and set relative risks in context with population prevalence estimates. It also provides important evidence for generating case definitions to support public health risk assessment, clinical triage and diagnostic algorithms.Competing Interest StatementAll authors have completed the ICMJE Conflicts of Interest form and declare: no support from any organisation for the submitted work; JMcM reports grant funding from IMOVE COVID-19, no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThe analysis using CPRD data was funded by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England (PHE). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or PHE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesApplications for relevant anonymised data should be submitted to the Public Health England Office for Data Release: https://www.gov.uk/government/publications/accessing-public-health-england-data/about-the-phe-odr-and-accessing-data